Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06352619 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial

Study acronym: ENCHANTED3/MT
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: May 2026 to Dec 2027 Completion date: May 2026 to May 2028v6 Show 1 more changeShow less
    • Completion date: May 2026 to May 2028
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 2024 to Oct 11, 2024 · Study sites: 0 to 2v5 Show 2 more changesShow less
    • Start date changed from estimate of May 2024 to Oct 11, 2024
    • Study sites: 0 to 2
  3. Primary and study completion dates: Apr 2026 to May 2026 Start date: Apr 2024 to May 2024v4 Show 1 more changeShow less
    • Start date: Apr 2024 to May 2024
  4. Study Status, Referencesv3
  5. Secondary endpoints revised (9) Study description expanded, about 90 words · Study title shortened, about 7 wordsv2 Show 2 more changesShow less
    • Study description expanded, about 90 words
    • Study title shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The George Institute
19 trials monitored
See 1 trial at risk
Stroke
3,289 trials monitored
See 141 trials at risk
Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \<130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3/MT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3/MT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \[≥180mmHg\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \[150-160mmHg\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management.
Trial Details
NCT Number NCT06352619
Lead Sponsor The George Institute
Collaborators: University of Calgary, Changhai Hospital
Conditions Ischemic Stroke, Acute
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov